Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer
Pathology & Oncology Research · 02.03.2026 · 32
DOI: 10.3389/pore.2026.1612333 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology & Oncology Research, online erschienen am 02.03.2026. Verfasst von Melinda Váradi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Biomarkers, Tumor. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovációs és Technológiai Minisztérium.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI) therapy has become a firmly integrated component of the systemic treatment repertoire for locally advanced and metastatic urothelial bladder cancer (UBC). Over the past decade, multiple ICIs have demonstrated meaningful clinical activity, and their indications have expanded across treatment lines, including second-line therapy after platinum, first-line therapy for cisplatin-ineligible disease, avelumab maintenance following chemotherapy, and, more recently, combination strategies such as pembrolizumab plus enfortumab vedotin. Despite these advances, patient responses to ICIs remain highly heterogeneous. While a subset of patients achieves substantial tumor regression and long-term survival, a considerable proportion derives little or no benefit. The rapidly evolving therapeutic landscape - encompassing antibody-drug conjugates, targeted agents, and perioperative ICI approvals - further emphasizes the need to identify which patients are most likely to respond to immunotherapy. Given the marked variability in therapeutic sensitivity and the increasing availability of alternative effective treatments, accurate prediction of ICI efficacy is becoming increasingly crucial for personalized treatment selection. In this review, we provide a comprehensive overview of currently established and emerging biomarkers of ICI response in UBC, including PD-L1 immunohistochemistry, serum inflammatory markers, tumor mutational burden, histology and molecular subtypes, gene expression patterns and microbiome features. We discuss their strengths, limitations, and potential translational relevance, highlighting ongoing challenges and future directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Semmelweis University, Budapest, Hungary.
- Institute of Pathology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
- Department of Urology, University of Duisburg-Essen, Essen, Germany.
- Department of Genitourinary Medical Oncology and Pharmacology, National Institute of Oncology, Budapest, Hungary.
Förderung
- Innovációs és Technológiai Minisztérium
Zitieren
APA
Váradi, M., Magyar, B., Széles, Á., Korda, S., Németh, B., Simon, B., Reis, H., Oláh, C., Horváth, O., Dér, B., Nyirády, P., & Szarvas, T. (2026). Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer. Pathology & Oncology Research, 32. https://doi.org/10.3389/pore.2026.1612333
Vancouver
Váradi M, Magyar B, Széles Á, Korda S, Németh B, Simon B, et al. Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer. Pathology & Oncology Research. 2026;32. doi:10.3389/pore.2026.1612333
BibTeX
@article{Vradi2026,
author = {Váradi, Melinda and Magyar, Balázs and Széles, Ádám and Korda, Sára and Németh, Bernadett and Simon, Barbara and Reis, Henning and Oláh, Csilla and Horváth, Orsolya and Dér, Bálint and Nyirády, Péter and Szarvas, Tibor},
title = {Prognostic and predictive factors of immune checkpoint inhibitor therapy in urinary bladder cancer},
journal = {Pathology & Oncology Research},
year = {2026},
volume = {32},
doi = {10.3389/pore.2026.1612333}
}
EUVIMED